STUDY-RELATED TRAVEL WILL BE PROVIDED AT NO COST TO MANY STUDY PARTICIPANTS AND THEIR STUDY PARTNER INCLUDING FLIGHTS FROM ANYWHERE IN THE U.S., GROUND TRANSPORTATION, LODGING, AND MEALS FOR BOTH THE PATIENT AND CAREGIVER. TRAVEL ARRANGEMENTS AND REIMBURSEMENTS MAY VARY FROM STUDY TO STUDY.
Investigational Treatment for Progressive Supranuclear Palsy (PSP)
CenExel RMCR is conducting clinical studies that will provide many patients with a new investigational medication. The study seeks to determine if the investigational treatment will safely slow the progression of PSP.
Meet Dr Kumar – Watch the Video
Benefits of participating in clinical trials at no cost to you or your family:
- Lab Work
- Neurological Exams
- More Access to Physicians
- Investigational Medications (Placebo Controlled)
- Lodging and Meals
- Travel (Within US for caregiver & patient)
Informed Consent Is Very Important: Learn about the risks, benefits, and the clinical trials process by visiting our Clinical Trials Information Page.
A helpful resource about Progressive Supranuclear Palsy is CUREPSP
Progressive Supranuclear Palsy (PSP) is a rare neurodegenerative disease. Only five or 6 people per 100,000 will develop it. The exact cause of PSP is unknown, but the symptoms are caused by misfolding and accumulation of a naturally-occurring brain protein called tau. These accumulations become toxic and cause degeneration of brain cells.
PSP affects many aspects of a patient’s life. There a wide range of symptoms associated with this disease including slowness of movement, loss of balance, worsening of memory and thinking ability, personality changes, mood problems, problems with eye movements-particularly looking downwards, difficulty swallowing, slurred speech, and drooling. This disease is progressive, so symptoms emerge and worsen as the disease progresses.
PSP is difficult to diagnose because the early stages often look very similar to Parkinson’s disease. One of the main diagnostic features of this disease is visual complaints. Patients with PSP have difficulty looking up or down and often complain of double vision and involuntary closing of the eyelids. Other early complaints are unexplained falls, problems with memory and thinking, and mood problems including impulsiveness, apathy and depression. When diagnosing a patient with PSP, other similar disorders, which may be treatable, should be ruled out.
There is currently no FDA-approved treatment for PSP. Some patients may respond to anti-Parkinson medications. Levodopa may help with the slowness and stiffness, but the effect is generally much less than in Parkinson’s disease, the benefit usually diminishes significantly over time, and patients usually need a much higher dose of medication to receive benefit. Antidepressants may help mood problems in some patients. Some non-drug therapies which are helpful for some individuals include prism glasses for double vision, speech therapy, and walking aids. For patients with marked swallowing problems surgical placement of a feeding tube may help ensure nutrition and reduce the risk of pneumonia caused by food going into the lungs.
There is currently extensive research ongoing to better understand the cause and progression of PSP. It is thought that spread of misfolded tau from cell to cell plays an important role in the disease progression. We are currently conducting a clinical trial examining whether IV infusion of an antibody against tau will reduce spread of the abnormal protein and slow the progression of the disease. Patients who are able to walk 5 steps with minimal assistance and have had symptoms less than 5 years may be candidates for the study.
Do you or a loved one have PSP?
Please fill out the below survey to help us determine if you, or your loved one, may qualify for an investigational study aiming to potentially slow disease progression.